Metabolic disorders take a massive toll on human life.
Diabetes is the most widespread of these diseases. Currently, 347 million people worldwide suffer from diabetes, a number expected to jump by two-thirds by 2030. Disturbing on its own, this trend also guarantees increases in related conditions, including heart disease, stroke, blindness, neuropathy, kidney failure, and death.
Other conditions in this realm also pose serious health concerns. Hormone imbalances cause up to 6,000 endocrine disorders while diseases affecting the thyroid afflict more than 200 million people. Conditions, less common, but no less serious, such as Addison’s disease, Cushing’s syndrome, and Graves’ disease threaten thousands. There is also an increasing concern over human exposure to environmental chemicals that can disrupt endocrine function.
To develop new treatments and cures, medical researchers need fast, accurate, and innovative discovery and preclinical services.
MPI Research brings that specialized scientific expertise, from pharmacokinetic and ADME studies to robust in vivo and in vitro models, helping drive critical research on endocrine and metabolic disorders. Our commitment goes beyond merely being a research provider. We form strong relationships with our Sponsors and with R&D leaders in the field– to serve as a true partner.
MPI Research does more than offer the right technology and expertise; we share your passion for addressing these diseases. That passion provides a competitive edge for our Sponsors – and hope for patients across the globe.
- Streptozotocin (STZ)-induced diabetes
- Diet-induced obesity and diabetes
- High-fat diet/low-dose STZ-induced diabetes
- Genetic models, including ob/ob and db/db
- Diet-induced hypertriglyceridemia
- Non-alcoholic steatohepatitis (NASH)
- Chemical-induced weight gain
- Oral and intraperitoneal glucose tolerance tests
- Insulin tolerance test
- Lactate dehydrogenase (LDH) subtyping
- Histochemical and immunohistochemical tissue staining
- Selected biomarker identification (gene and protein expression patterns)
- Growth hormone-dependent hypophysectomized rat model
- Hyperparathyroidism (partial nephrectomized rats)
- Cyclophosphamide-induced neutropenia
Studies performed in the past 2 years